Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis

How Microbes, Mycobacteria, and Metastases May Alter the Way We Look at Rheumatic Diseases

Simon M. Helfgott, MD  |  October 1, 2012

Studying the relationships between microbes and their hosts, the role for Bacille Calmette Guerin (BCG) as a vaccine for Type I diabetes, and emotional stress and bone metastases

EULAR: Identify Arthritis Early, Treat it Effectively

Thomas R. Collins  |  October 1, 2012

Recent studies are uncovering genetic and environmental factors at play in the earliest stages of rheumatoid arthritis and medications that are effective in treating juvenile idiopathic arthritis

EULAR 2012: MicroRNAs’ Role in Rheumatic Diseases Coming into Sharper Focus

Thomas R. Collins  |  September 5, 2012

MicroRNAs are poised to play a big role in the future understanding and treatment of rheumatoid arthritis.

Coding Corner Question: September’s Coding Challenge

Staff  |  September 5, 2012

How the case is coded.

EULAR 2012: Rewards in Risk Factor Research

Thomas R. Collins  |  September 5, 2012

Investigations of infection and comorbidities offers hints to better understanding of rheumatoid arthritis.

Why Did Rheumatoid Arthritis Begin in 1800?

Staff  |  September 5, 2012

The connection between periodontal disease and RA.

Drug Updates: Lorcaserin, Acetaminophen, and More

Michele B. Kaufman, PharmD, BCGP  |  September 5, 2012

information on new approvals and medication safety

EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

Thomas R. Collins  |  August 8, 2012

Advances in the rheumatology clinic are promising, two experts say.

Partners in Advancing Rheumatology

James O’Dell, MD, and David I. Daikh, MD, PhD  |  August 8, 2012

The REF is making great strides in advancing treatment and finding cures for rheumatic disease.

Coding Corner Question: August Coding Challenge

Staff  |  August 8, 2012

A 43-year-old female established patient diagnosed with rheumatoid arthritis comes to the office for her first infliximab infusion.

  • « Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • 63
  • …
  • 74
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences